According to the bank's website, "the proposed IFC investment will support Brightgene’s expansion into Indonesia to meet the growing local demand in the country (the “Project”)". Moreover, "Brightgene Bio-Medical Technology Co., Ltd. (“Brightgene” or the “Company”) is a leading Chinese pharmaceutical company that focuses on the research and manufacturing of high barrier generics, active pharmaceutical ingredients (“APIs”), and finished dosage forms (“FDFs”)".
Director, PT BrightGene Biomedical Indonesia
Address (Physical): Karawang New Industry City, Block B No. 8 Jl. Trans Heksa Km.7, Karawang, West Java, 41361
ACCESS TO INFORMATION
You can submit a request for information disclosure at: https://disclosures.ifc.org/#/inquiries
If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.
ACCOUNTABILITY MECHANISM OF IFC/MIGA
The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org